INFLUENZA VIRUS STRAIN A/47/PANAMA/99/234 (H3N2) FOR PRODUCING LIVE ANTI-INFLUENZA INTRANASAL VACCINE FOR CHILDREN

FIELD: biotechnology, medicine, pediatrics. ^ SUBSTANCE: invention proposes the vaccine strain A/47/Panama/99/234 (H3N2) that represents reassortant prepared by breeding the epidemic virus A/Panama/2007/99/ (H3N2) with the cold adopted temperature-sensitive virus A/Leningrad/134/47/57 (H2N2) as attenuation donor that is harmless for children. The strain A/47/Panama/99/234 (H3N2) multiplies actively in developing chicken embryos at optimal temperature 33-34oC and characterized by sensitivity to temperature and adaptation to cold. From epidemic virus the reassortant inherited two genes encoding surface proteins (hemagglutinin and neuraminidase) and six genes encoding non-glycosylated proteins from the attenuation donor. The strain A/47/Panama/99/234 (H3N2) is areactogenic for children in its intranasal administration. The vaccine strain A/47/Panama/99/234 (H3N2) corresponds by its biological properties and reactogenic indices to requirements for vaccine strains in accordance to Pharmacopoeia article 42-3353-97 with respect to the live anti-influenza vaccine for intranasal applying for children of 3-14 years old. ^ EFFECT: valuable properties of strain. ^ 2 tbl, 1 dwg, 1 ex